WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. – Trademark Portfolio

Entity Type: 99

WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include UMYWJ. The owner is based in WENCHANG, HAINAN.

RM 1005, UNIT 2, BLDG 5, DIJINWAN

NO. 117, WENHANG ROAD, WENCHENG TOWN

WENCHANG, HAINAN 571399 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

UMYWJ
UMYWJ
Registered 2024

Trademark Classifications

WENCHANG MINGKANGCUI E-COMMERCE CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. have?

WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. file in?

WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are WENCHANG MINGKANGCUI E-COMMERCE CO., LTD.'s most well-known trademarks?

WENCHANG MINGKANGCUI E-COMMERCE CO., LTD.'s registered trademark portfolio includes well-known marks such as UMYWJ. These are among 1 currently registered trademark in the portfolio.

What is WENCHANG MINGKANGCUI E-COMMERCE CO., LTD.'s trademark registration success rate?

WENCHANG MINGKANGCUI E-COMMERCE CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.